Correlation of Serum CA-125 Marker with Histopathological Findings in Ovarian Tumors
Authors
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Objective: To evaluate the correlation between serum CA-125 levels and histopathological findings in ovarian tumors. Design: Prospective descriptive study. Subjects/Patients: A total of 59 patients with radiologically diagnosed ovarian tumors, presenting between May 2023 and October 2024, were included. Methods: Serum CA-125 levels were measured pre-operatively, and histopathological examination was performed post-surgery. Data were analyzed to assess the association between CA-125 levels and tumor type. Results: Of the 59 cases, 42 (71.18%) were benign, 15 (25.42%) malignant, and 2 (3.38%) borderline. Mean CA-125 levels were significantly higher in malignant tumors (406.38 ± 372.43 U/mL) compared to benign (28.79 ± 22.16 U/mL). Malignancy was more common in postmenopausal women. CA-125 levels were highest in high-grade serous carcinoma (888.96 ± 92.93 U/mL). Elevated CA-125 (>35 U/mL) showed a sensitivity of 93.33%, specificity of 76.19%, and accuracy of 80.70% for malignancy prediction. Conclusion: Serum CA-125 is a valuable biomarker in distinguishing malignant from benign ovarian tumors, especially in postmenopausal women and surface epithelial tumors.
##plugins.themes.bootstrap3.article.details##
Copyright (c) 2025 Dr. Tanvi Tailor, Dr. Toral Jivani, Kiah Jivani
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons License All articles published in Annals of Medicine and Medical Sciences are licensed under a Creative Commons Attribution 4.0 International License.
Dr. Tanvi Tailor, Third Year Resident Doctor, Department of Pathology, Surat Municipal Institute of Medical Education & Research, Surat 395010, India.
Third Year Resident Doctor, Department of Pathology, Surat Municipal Institute of Medical Education & Research, Surat 395010, India.
Dr. Toral Jivani, Associate Professor, Department of Pathology, Surat Municipal Institute of Medical Education & Research, Surat 395010, India.
Associate Professor, Department of Pathology, Surat Municipal Institute of Medical Education & Research, Surat 395010, India.
Kiah Jivani, Second Year MBBS Student, B.J. Medical College, Ahmedabad, Gujarat, India.
Second Year MBBS Student, B.J. Medical College, Ahmedabad, Gujarat, India.
[1] National Cancer Registry Programme. (2020). Consolidated report of the population-based cancer registries: 2020. Indian Council of Medical Research.
[2] International Agency for Research on Cancer. (2020). Globocan 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020. World Health Organization. https://gco.iarc.fr/
[3] Robbins, S. L., Cotran, R. S., Kumar, V., Abbas, A. K., & Aster, J. C. (2015). Pathologic basis of disease. Saunders Elsevier.
[4] Das, M. K., & Ghimire, S. (2018). Histopathological study of ovarian lump and serum tumor marker Ca 125 estimation as a screening tool. Journal of Nobel Medical College, 7(1), 30-36. https://doi.org/10.3126/jonmc.v7i1.20844
[5] Morales-Vásquez, F., Pedernera, E., Reynaga-Obregón, J., López-Basave, H. N., Gómora, M. J., Carlón, E., Cárdenas, S., Silva-Ayala, R., Almaraz, M., & Méndez, C. (2016). High levels of pretreatment CA125 are associated with improved survival in high-grade serous ovarian carcinoma. Journal of Ovarian Research, 9, 41. https://doi.org/10.1186/s13048-016-0247-6
[6] Patil, R. K., Bhandari, B., Kittur, S. K., Haravi, R. M., S, A., & Jadhav, M. N. (2017). Histomorphological study of ovarian tumors: At a tertiary care centre. APALM, 4, A638-A645. https://doi.org/10.21276/APALM.1412
[7] Patel, N., Bavikar, R., & Ingale, Y. P. (2024). Histomorphologic analysis of ovarian tumors according to the new 2020 WHO classification of female genital tumors. Journal of Cancer Research and Therapeutics, 20, 966-971. https://doi.org/10.4103/jcrt.jcrt_2607_22
[8] Rao, P. S., Sharma, P., Mogra, N., & Talreja, K. (2020). Histopathological study of ovarian tumours in a tertiary healthcare centre of Southern Rajasthan. IJPO, 7, 561-566. https://doi.org/10.18231/j.ijpo.2020.112
[9] Bhagat, S., Majumdar, P., Bhattacharjee, P., & Raj, R. (2024). CA125 and ovarian neoplasm: Do they tally in the rally? Study in Eastern India. Research Journal of Medical Sciences (Res. J. Med. Sci.), 18, 343-346. https://doi.org/10.59218/makrjms.2024.4.343.346
[10] Agarwal, D., Kaur, S., Agarwal, R., & Gathwal, M. (2018). Histopathological analysis of neoplastic lesions of the ovary: A 5-year retrospective study at a tertiary health care centre. IJCMR, 5. https://doi.org/10.21276/ijcmr.2018.5.5.36
[11] Pant, H., Prakash, A., Khandelwal, R., & Pandey, S. (2019). Correlation of serum CA-125 with histopathological findings in ovarian tumors. JDPO, 4, 81-85. https://doi.org/10.18231/j.jdpo.2019.016
[12] Shintre, S. A., Survase, R. M., Patil, N. A., & Sayyed, R. (2017). Effectiveness of risk of malignancy index to differentiate benign from malignant ovarian masses: A cross- sectional study. International Journal of Health Sciences and Research, 7.
[13] Marachapu, J., & Vij, S. (2023). Histomorphological spectrum of ovarian lesions from a single institute. International Journal of Research in Medical Sciences, 11, 1141-1145. https://doi.org/10.18203/2320-6012.ijrms20230851
[14] K, A., Patil, A. G., A. M., & Devarmani, S. (2021). Histopathological spectrum of ovarian neoplasms and their clinicopathological correlation. International Journal of Health and Clinical Research, 4, 125-128.
[15] Habib, K. A., Jumaa, M. G., & Hussein, M. J. (2015). Determination of serum CA125 and evaluation of its efficiency as a screening tool for early detection of ovarian tumors. Baghdad Science Journal, 12.
[16] Verma, N., Tiwari, V., Sharma, S. P., Singh, P., Rathi, M., & Gupta, T. (2018). Clinico-pathological correlation of ovarian tumors and tumor-like lesions with the role of CA125 and HE4 as biomarkers for discrimination of benign and malignant ovarian tumors. International Journal of Research in Medical Sciences, 6, 2238.
[17] Neogi, S. S., & Srivastava, L. M. (2014). Elevated tumour marker CA125: Interpretations in clinical practice. Current Medicine Research and Practice, 4, 214-218. https://doi.org/10.1016/j.cmrp.2014.09.004
[18] Kayastha, S. (2009). Study of ovarian tumours in Nepal Medical College Teaching Hospital. Nepal Medical College Journal, 11, 200-202.